SulTlmary
We studied the effects of histamine on human immunoglobulin (IgE) and IgG4 production. Histamine selectively enhanced IgE and IgG4 production in purified surface IgE and IgG4 negative (slgE-slgG4-) B ceils from normal donors stimulated with interleukin (IL)-4 plus anti-CD58 or IL-13 plus anti-CD58 monoclonal antibody (mAb) without affecting production of IgG1, IgG2, IgG3, IgM, IgA1, or IgA2. In cultures with IL-4 plus anti-CD58 mAb, histamine-induced enhancement of IgE and IgG4 production was specifically blocked by thioperamide (H3 receptor antagonist), and was inhibited by anti-IL-10 antibody (Ab). In contrast, in cultures with IL-13 plus anti-CD58 mAb, histamine-induced enhancement was blocked by dimaprit (H1 receptor antagonist), and was inhibited by anti-IL-6 mAb. Histamine also enhanced IgE and IgG4 production by in vivo-generated slgE + and slgG4 + B cells, respectively, from atopic patients; enhancement was blocked by dimaprit and thioperamide, and was inhibited by anti-IL-6 mAb and anti-IL-10 Ab. In slgE-slgG4-B ceils, IL-4 plus anti-CD58 mAb induced IL-10 production and IL-10 receptor expression, whereas IL-13 plus anti-CD58 mAb induced IL-6 production and IL-6 receptor expression. Histamine increased IL-10 and IL-6 production without affecting IL-10 and IL-6 receptor expression, in cultures with IL-4 plus anti-CD58 mAb and with IL-13 plus anti-CD58 mAb, respectively, which was blocked by thioperamide and dimaprit, respectively. In contrast, slgE + and slgG4 + B cells spontaneously produced both IL-6 and IL-10 and constitutively expressed IL-6 and IL-10 receptors, and histamine increased IL-6 and IL-10 production without affecting IL-6 or IL-10 receptor expression, which was blocked by thioperamide and dimaprit. These results indicate that histamine enhanced IgE and IgG4 production by increasing endogenous IL-6 and IL-10 production via H, and H 3 receptors, respectively.
M
any cytokines and factors are involved in human IgE .and IgG4 production. IL-4 induces IgE and IgG4 production in purified B cells stimulated with anti-CD40 mAb, or hydrocortisone by isotype switching (1) (2) (3) (4) (5) . IL-6, IL-10, and TNF-o~ enhance IL-4-induced IgE and IgG4 production in such cultures, whereas IL-8, and TGF-[3 inhibited IgE and IgG4 production (3, (6) (7) (8) (9) . In contrast, IL-5, IL-9, IL-12, IFN-ot, and IFN-% which either enhance or inhibit IgE and IgG4 production induced by IL-4 in T cell-dependent culture, have no effect on IgE and IgG4 production in purified B cells (9) (10) (11) (12) . These results indicate that there are various IgE-and IgG4-modulatory factors in IL-4--stimulated cultures. Recently, in addition to IL-4, IL-13 has been shown to induce IgE and IgG4 production in purified B cells stimulated with anti-CD40 mAb (13, 14) . We have reported that IL-13 induces IgE and IgG4 production in purified B cells stimulated with hydrocortisone (9, 15) . Moreover, anti-CD58 mAb was also found to induce IgE production in IL-4--stimulated cultures (16) . However, the effects of various cytokines on IgE and IgG4 production induced by IL-4 plus anti-CD58 mAb or by IL-13 plus anti-CD58 mAb have not been studied in depth.
Histamine is an autocoid released from mast cells and basophils by IgE-and IgG4-dependent stimulation (17, 18) . It has been reported that histamine modulates production of cytokines by various cells, and that it enhances production of IL-6 and IL-8 by B and endothelial cells, respectively, whereas it inhibits TNF-o~ production by monocytes (19) (20) (21) . In addition, histamine inhibits human IgG and IgM production in purified B ceils stimulated with Sta-phylococcus aureus Cowan strain I plus IL-2, or in mononuclear cells stimulated with pokeweed mitogen (22, 23) . In contrast, histamines were found to either inhibit or enhance IgG or IgM production in human B cell lines (22, 24) . These findings indicate that histamine differentially modulates Ig production depending on stimuli of target B cells. Since the effect of histamine on IgE and IgG4 production has not yet been reported, we examined the effect of histamine on their production in human B cells stimulated with IL-4 plus anti-CD58 mAb, or with IL-13 plus anti-CD58 mAb. Modulation of the effect of histamine by various cytokines is also discussed.
Materials and Methods
Reagents. Histamine dihydrochloride (HIS) l, diphenhydranfine (DIP, H t receptor antagonist), dimaprit (DIM, H2 receptor agonist), cimetidine (CIM, H 2 receptor antagonist), (tL)-0~-methylhistamine (RAM, H3 receptor agonist), and thioperamide (THI, H3 receptor antagonist) were purchased from Sigma Chemical Co. (St. Louis, MO). 2-methylhistamine (MET, H 1 receptor agonist) was kindly provided by Smith Kline & French (Philadelphia, PA). The following recombinant human cytokines and Abs were kindly provided by companies noted previously (1, 9, 14) : IL-4 and rabbit anti-IL-4 Ab (Ono Pharmaceutical Company, Osaka, Japan), IL-2 and IFN-~x (Takeda Chemical Industries, Osaka), and growth hormone and rabbit anti-growth hormone Ab (Sumitomo Pharmaceutical Company, Osaka, Japan). Recombinant human IL-13 was purchased from Pepro Tech Inc. (Rocky Hill, NJ). Recombinant human IL-6, IL-9, IL-10, IL-12, IFN-y, and TGF-]3, and mouse IgG1 anti-IL-6 and goat anti-IL-10 Ab were purchased from IL&D Systems, Inc. (Minneapolis, MN). Mouse IgM anti-CD40 mAb (BL-C4), mouse IgG2a anti-CD58 mAb (BRIC5), and rabbit anti-IL-13 Ab were purchased from Cosmo Bio Co. (Tokyo, Japan). The culture medium was DME, supplemented with Ham's Nutrient (DME/F-12; Sigma Chemical Co.), 0.5% BSA, and 50 Ixg/ml transferrin (9, 14) .
Cell Cultures. Tonsillar mononuclear cells were obtained from nonatopic donors (serum IgE level <50 U/ml) and atopic patients (serum IgE level 1,578-12,259 IU/ml). Then, highly purified B ceils were separated by S1LBC rosetting, followed by k-leucine methyl ester incubation, as described previously (9, 14) . Purified B cell fractions contained <1% CD3 + T cells, <1% C1)14 + monocytes, <1% CD16 + NK cells, and >98% CD20 + B cells. Purified B cells were further separated into small resting B cells by Percoll density centrifugation, and small B cells were depleted of surface IgE-positive (slgE +) and slgG4 + B cells by panning (9, 14) . The percentage of sIgE + and slgG4 + B cells was <0.1%. These slgE-slgG4-B cells were cultured (2 • 105/0.2 ml/well) in U-bottomed microtiter plates (Costar Corp., Cambridge, MA) for 14 d in the presence or absence of various factors as described in tt, esults. Alternatively, slgE +, slgE-, slgG4 +, and slgG4 B cells were purified from tonsillar B cells of atopic patients by panning. The percentages, respectively, of slgE + and slgG4-B cells in the slgE-and slgG4 B cell fractions were <0.1%. On the other hand, purified slgE + and slgG4 + B cell 1Abbreviations used in this paper: CIM, cimetidine; DIM, dimaprit; DIP, diphenhydramine; HIS, histamine; MET, 2-methylhistamine; MFI, mean fluorescence intensiw; RAM, (R)-oL-methylhistamine; sIgE +, surface IgE positive; THI, thioperamide.
fractions contained >98% slgE + B cells and >98% slgG4 + B cells, respectively (9, 14) . Purified slgE +, slgE , slgG4 +, and slgG4-B cells were cultured (2 • 104/0.2 ml/well) for 14 d as described in Results. Control cultures for the evaluation of preformed Ig were carried out in the presence of cycloheximide (100 Ixg/ml). The amounts oflgE, IgG, IgM, and IgA subclasses in the supernatants were determined by ELISA (9, 15) . In some experiments, slgE-slgG4-, slgE +, and slgG4 + B cells were cultured (2 • 10s/0.2 ml/well) with various factors for 2 d, and the production oflL-6 and IL-10 was determined by ELISA (tL&D Systems, Inc.). Simultaneously, the binding of IL-6, IL-10, (l<)-ot-methylhistamine, and diphenhydramme to those cells was studied by using biotinylated IL-6 and IL-10 (P,&D Systems, Inc.), and biotinylated (R)-ec-methylhistamine and diphenhydramine as previously reported (9) . The mean fluorescence intensity (MFI) value ofbiotinylated factor~specific binding, determined after the subtraction ofnonspecific binding in the presence of a 100-fold excess of unlabeled factors, was expressed as AMFI (9) .
In Vivo Effect of Antihistamine on IgE and lgG4 Production in
Atopic Patients. Four atopic patients (patients with atopic dermatiffs, serum IgE level 2,344-5127 IU/ml, age 15-45-yr old) were treated with oral antihistanfine (clemastine, 6 mg/d) and nonsteroidal anti-inflammatory ointment (bufexamac ointment). Alternatively, three atopic patients (patients with atopic dermatitis, serum IgE level 1,168-3685 IU/ml, age 16-32-yr old) were treated with bufexamac ointment alone. Peripheral blood was drawn before and after 2 wk of each treatment, and large B cells were pnrifled as above. They were cultured (2 • 10s/0.2 ml/well) with medium alone for 14 d, and the amount of IgE and IgG4 in the supernatants were determined by ELISA (9, 15).
Results and Discussion
Initial experiments have shown that histamine, either alone or with IL-4, IL-13, or anti-CD58 mAb, did not induce production of IgE (<0.2 ng/ml, n = 10) or IgG4 (<0.3 ng/ml, n = 10) by slgE-slgG4-B cells. However, as shown in Fig. 1 A, histamine enhanced IgE and IgG4 production induced by IL-4 plus anti-CD58 mAb in a dosedependent fashion. In contrast, histamine did not affect production oflgM, IgG1, or IgG2 ( Fig. 1 B) or IgA1, IgG3, or IgA2 ( Fig. 1 C) . Identical results were observed in cultures stimulated with IL-13 plus anti-CD58 mAb. Histamine selectively enhanced production of IgE and IgG4 in a dosedependent fashion (Fig. 1 D) , without affecting production oflgM, IgG1, IgG2, IgG3, IgA1, or IgA2 ( Fig. 1 , E and F). In 10 experiments, histamine (10 -5 M) enhanced production of IgE (264 + 87% enhancement) and IgG4 (245 + 92% enhancement) induced by IL-4 plus anti-CD58 mAb, while it enhanced production of IgE (378 + 95% enhancement) and IgG4 (321 + 102% enhancement) induced by IL-13 plus anti-CD58 mAb. In contrast, histamine did not enhance (<20% enhancement) production of IgM, IgG1, IgG2, IgG3, IgA1, or IgA2 in these cultures (n = 10).
It has been reported that histamine modulates Ig production or cytokine synthesis through one of the H1, H> or H 3 receptors, or through more than one type of receptor (19) (20) (21) (22) (23) (24) . To study which receptors were involved in enhancement of IgE and IgG4 production, B cells were stimulated with histamine, and HI, H2, and H 3 receptor antagonist IIL-4 + AntI-CD 58 mAbl <~-13 + Anti-CD 58 mA~ were added. As shown in Fig. 2 A, left, in cultures stimulated with IL-4 plus anti-CD58 mAb, histamine-induced IgE and IgG4 production was not affected by diphenhydramine (DIP, H1 receptor antagonist) or cimetidine (CIM, H 2 receptor antagonist), whereas enhancement was completely blocked by thioperamide (THI, H 3 receptor antagonist).
We have previously reported that, in purified B cells, IL-4 plus hydrocortisone or IL-13 plus hydrocortisone induced IgE and IgG4 production, and this production was enhanced by IL-6 and IL-10. In contrast, other cytokines, IL-1]3, IL-2, IL-3, IL-5, IL-7, IL-9, IL-11, or IL-12 did not enhance IgE or IgG4 production (9) . In addition, nerve growth factor or growth hormone, which enhanced IgE and/or IgG4 production (1, 13), were without effect (data not shown). It is thus possible that histamine-induced enhancement was due to production of IL-4, IL-6, IL-10, or IL-13. As shown in Fig. 2 A, so. In contrast, in cultures stimulated with IL-13 plus anti-CD58 mAb, histamine-induced enhancement of IgE and IgG4 production was blocked by diphenhydramine, but not by cimetidine or thioperamide. Moreover, anti-IL-6 mAb, but not anti-IL-4 mAb or anti-IL-10 Ab, inhibited histamine-induced enhancement, and anti-IL-13 Ab abrogated IgE and IgG4 production (Fig. 2 A, right) .
We then studied the specificity of the effects of IL-6 and IL-10. As shown in Fig. 2 B, left, in cultures stimulated with IL-4 plus anti-CD58 mAb, addition of IL-10, but not IL-6, enhanced IgE and IgG4 production. Histamineinduced enhancement was blocked by anti-IL-10 Ab, which was reversed by high concentrations of IL-10, but not by IL-6. In contrast, in cultures stimulated with IL-13 plus anti-CD58 mAb, IL-6 enhanced IgE and IgG4 production. Anti-IL-6 blocked histamine-induced enhancement, which was reversed by IL-6, but not by IL-10. Collectively, these results indicated that in cultures stimulated with IL-4 plus anti-CD58 mAb, histamine enhanced IgE and IgG4 production through H 3 receptors and by involvement oflL-10, but not oflL-6. This is in accordance with the previous report by others (16) that IL-6 did not affect IgE production induced by IL-4 plus anti-CD58 mAb. In contrast, in cultures stimulated with IL-13 plus anti-CD58 mAb, histamine enhanced IgE and IgG4 production through H l receptors and by involvement of IL-6.
It is possible that histamine enhanced IgE and IgG4 production by affecting isotype switching ofslgE-and slgG4-B cells, respectively, or alternatively, by directly affecting slgE § and slgG4 § B cells, respectively. To test this, we took advantage of the fact that in vivo-generated slgE + and slgG4 +, but not slgE-and slgG4-B cells obtained from atopic patients spontaneously produced IgE and IgG4, respectively (1, 14, 15) . As shown in Fig. 3 A, Expt. 1, histamine enhanced IgE production by slgE § B cells, which was blocked by diphenhydramine and thioperamide, whereas cimetidine and IFN-~/failed to do so. Other inhibitory cytokines, IL-12, IFN-ot, TGF-[3, and Abs to stimulatory cytokines, including antigrowth hormone, antinerve growth factor, and anti-IL-9 Abs were also without effect (data not shown). However, histamine failed to induce IgE production by slgE-B cells (Fig. 3 A, Expt. 1 ). On the other hand, spontaneous IgE production by slgE + B cells was not inhibited by anti-lL-4 mAb or anti-IL-13 Ab, whereas it was inhibited by anti-IL-6 mAb and anti-IL-10 Ab. Moreover, anti-IL-6 m_Ab and anti-IL-10 Ab each inhibited histamine-induced enhancement of lgE production (Fig. 3 A, Expt. 2). Furthemlore, simultaneous addition of anti-IL-6 mAb and anti-IL-10 Ab almost completely inhibited spontaneous and histamine-induced lgE production by slgE + B ceils. IL-6 or IL-10 each partially reversed inhibition by anti-IL-6 mAb plus anti-IL-10 Ab. However, addition of both IL-6 and IL-10 completely reversed inhibition of lgE production. In contrast, histamine with these factors failed to induce IgE production by slgE-B cells (Fig. 3 A, Expt. 3) . Moreover, histamine with IL-4, IL-t3, or anti-CD58 mAb did not induce IgE production by slgE-B cells (<0.2 ng/ ml) as observed by slgE-B cells from nonatopic donors.
As shown in Fig. 3 B, Expts. 1-3, identical results were observed for IgG4 production by slgG4 + and slgG4-B cells. Spontaneous IgG4 production by slgG4 + B cells was enhanced by histamine, IL-6, and IL-10, whereas it was inhibited by anti-IL-6 mAb or anti-IL-10 Ab, but not by anti-IL-4 mAb or anti-IL-13 Ab. Histamine-induced enhancement was blocked by diphenhydramine and thioperamide, but not by dimaprit, and was inhibited by anti-IL-6 mAb and anti-IL-10 Ab. Addition of both IL-6 and IL-10 reversed inhibition by anti-IL-6 mAb plus anti-IL-10 Ab, whereas histamine with these factors failed to induce IgG4 production by slgG4-B cells (Fig. 3, Expt. 3). Histamine with IL-4, IL-13, or with anti-CD58 mAb also failed to induce IgG4 production by slgG4-B cells (<0.3 ng/ml). Taken together, these results indicated that histamine enhanced IgE and IgG4 production by directly affecting slgE + and slgG4 + B cells, respectively, via both H1 and H 3 receptors and by involvement of IL-6 and IL-10.
It is possible that histamine-induced enhancement of IgE and IgG4 production was due to the increase in IL-6 and/ or IL-10 production, or alternatively, due to the enhanced expression of IL-6 and/or IL-10 receptors, in slgE + and slgG4 + B cells, respectively. To study this possibility directly, we stimulated slgE-slgG4-B cells from nonatopic donors with IL-4 plus anti-CD58 m_Ab, or with IL-13 plus anti-CD58 mAb. Alternatively, slgE* and slgG4 + B cells from atopic patients were cultured with medium. These cells were incubated with histamine in the presence or absence of histamine receptor antagonists or agonists, and production of IL-6 and IL-10, and IL-10 receptor expression were determined. In slgE-slgG4-B cells, medium alone did not induce production oflL-6 or IL-10 (<0.01 ng/n'fl), or expression of IL-6 or IL-10 receptors. However, as shown in Fig. 4 A, IL-4 plus anti-CD58 mAb induced IL-10 production and IL-10 receptor expression, whereas it failed to induce IL-6 production or IL-6 receptor expression. Histamine enhanced IL-10 production without affecting IL-10 receptor expression, whereas histamine failed to induce IL-6 production or IL-6 receptor expression. Histamineinduced enhancement of IL-10 production was blocked by thioperamide, but not by dimaprit. Moreover, whereas 2-methylhistamine (MET, H 1 receptor agonist) or dimaprit (DIM, H2 receptor agonist) failed to enhance IL-10 production, (R)-oe-methylhistamine (RAM, H 3 receptor agonist) did enhance production. On the other hand, IL-13 plus anti-CD58 mAb induced IL-6 production and IL-6 receptor expression, while having no effect on IL-10 production or IL-10 receptor expression. Histamine enhanced IL-6 production without affecting IL-6 receptor expression, and enhancement was blocked by diphenhydramine, but not by thioperamide. In addition, (P,)-oL-methylhistamine enhanced IL-6 production, whereas 2-methylhistamine or dimaprit failed to do so (Fig. 4 B) . In contrast, as shown in Fig. 4 , C and D, slgE + and slgG4 + B cells from atopic patients spontaneously produced both IL-6 and IL-10, and expressed IL-6 and IL-10 receptor. Histamine enhanced production of IL-6 and IL-10 without affecting receptor expression, which was specifically blocked by diphenhydramine and thioperamide, respectively. Moreover, 2-methylhistamine and (P,.)-ot-methylhistamine, respectively, enhanced production of IL-6 and IL-10 without affecting IL-6 and IL-10 receptor expression. Taken together, enhancement of IgE and IgG4 production by histamine was due to the increase in production of IL-6 and/or IL-10, but not due to the increased expression of IL-6 and IL-10 receptors.
In these studies, we have demonstrated that histarmne selectively enhanced IgE and IgG4 production. However, the mechanisms of the histamine-induced enhancement differed depending on the culture systems used. In cultures of slgE-slgG4 B cells stimulated with IL-4 plus anti-CD58 mAb, histamine-induced enhancement was due to the increased production of IL-10 through H 3 receptors. This is not surprising. It has been reported that, in addition to functional presynaptic autoreceptors in the brain cortex, H 3 receptors were involved in IL-8 secretion by endothelial cells, contractions of the ileum, and corticosterone secretion by the adrenal cortex (20, 25, 26) . To the best of our knowledge, this is the first report that H 3 receptors were involved in IL-10 production, resulting in enhancement oflgE and lgG4 production. In accordance with this, as shown in Fig. 5 , although H 3 receptors were not expressed on freshly separated sIgE-slgG4-B cells (<3 AMFI), they were induced by IL-4 plus anti-CD58 mAb, but not by IL-13 plus anti-CD58 mAb (<3 AMFI). In contrast, H 3 receptors were constitutively expressed on in vivo-generated slgE + and slgG4 + B cells.
On the other hand, in cultures stimulated with IL-13 plus anti-CD58 mAb, histamine enhanced IgE and IgG4 production through increased production of IL-6 via H 1 receptors. This is in accordance with the report that (a) IL-13 increased IL-6 production by human keratinocytes, and (b) histamine enhanced IgM production through increased production of IL-6 via H I receptors in B cells (24, 27) . Moreover, as shown in Fig. 5 , H1 receptors were not expressed on slgE-slgG4-B cells (<3 AMFI), however, they were induced by IL-13 plus anti-CD58 mAb, but not by IL-4 plus anti-CD58 mAb (<3 AMFI). In contrast, H I receptors were expressed constitutively on in vivo-generated slgE + and slgG4 + B cells. Taken together, these results suggested that in vivo IgE and IgG4 production was regulated by both IL-6 and IL-10, whereas in vitro IgE and IgG4 production induced by IL-13 or IL-4 plus anti-CD58 mAb was regulated by IL-6 or IL-10 independently. Although we and others have reported that IL-6 and IL-10 enhance in vitro IgE and IgG4 production in various culture systems (3, 5, 6, 9) , the direct evidence of the effect oflL-6 and IL-10 on in vivo IgE and IgG production in humans has not been previously reported. However, IL-6 is released locally in antigen-challenged sites in atopic patients (28) . IL-10 is overexpressed in the skin of patients with atopic dermatitis (29) . It is possible that in atopic patients, production oflL-6 and IL-10 is increased at the local site, which may enhance IgE and IgG4 production there, thus resulting in aggravating IgE-and IgG4-mediated allergic reactions (18) . This possibility is currently under investigation.
The fact that histamine enhanced IgE and IgG4 production stimulated with IL-4 or IL-13 is important in relation to the treatment of allergic diseases. It has been reported that IL-4 increased histamine release from basophils (30) . In addition, we have found that IL-13 (500 ng/ml) also increases histamine release from human basophils (21 + 6%, n = 4). Conversely, IgE and IgG4 were also involved in histamine release and IL-4 production (18, 31) . Therefore, it is tempting to speculate that, in atopic patients, IL-4, IL-13 and histamine may produce a vicious circle. Treatment with antihistamines may decrease IgE and IgG4 production, resulting in improvement of allergy. Therefore, we studied the effect of oralantihistamine on IgE and IgG4 production in atopic patients. As shown in Fig. 6 , spontaneous IgE production by B cells from atopic patients treated with oral H 1 receptor antagonist, clemastine (and nonsteroidal anti-inflammatory ointment, bufexamac) for 14 d, was decreased after treatment. Similarly, spontaneous IgG4 production by B cells from atopic patients decreased after treatment with clemastine (Fig. 6 A) . In contrast, IgE and IgG4 production by B cells from atopic patients treated with bufexamac ointment alone, as controls, was not decreased after treatment. These results indicate that histamine may affect IgE and IgG4 production in vivo. Studies on the detailed mechanisms as well as molecular analysis for the effect of histamine are currently in progress. Finally, histamine seems to be an excellent reagent for the study of IgE and IgG4 production.
